MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
35.70
-2.74
-7.12%
After Hours: 35.70 0 0.00% 16:10 05/15 EDT
OPEN
38.35
PREV CLOSE
38.43
HIGH
38.35
LOW
33.81
VOLUME
46.24K
TURNOVER
--
52 WEEK HIGH
44.00
52 WEEK LOW
14.00
MARKET CAP
140.60M
P/E (TTM)
-11.1470
1D
5D
1M
3M
1Y
5Y
1D
vTv Therapeutics: Buy Rating Reiterated on Favorable Risk-Reward and Clinical Momentum; $67 Price Target Unchanged
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT), Waters (WAT) and Alpha Teknova (TKNO)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT), Brookdale Senior Living (BKD) and Longeveron (LGVN)
TipRanks · 1d ago
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program
TipRanks · 1d ago
VTV THERAPEUTICS, INC. <VTVT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $45 FROM $47
Reuters · 1d ago
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)
TipRanks · 2d ago
vTv Therapeutics Expands At-The-Market Share Program Capacity
TipRanks · 2d ago
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.